Assembly Biosciences (NASDAQ:ASMB) Announces Quarterly Earnings Results, Beats Expectations By $0.55 EPS

Assembly Biosciences (NASDAQ:ASMB) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.12) by $0.55, Zacks reports. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.

Assembly Biosciences Stock Down 1.5 %

NASDAQ ASMB traded down $0.16 during trading on Thursday, reaching $10.69. 5,938 shares of the company traded hands, compared to its average volume of 24,351. The stock’s 50 day moving average price is $13.13 and its two-hundred day moving average price is $15.21. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th.

Insider Buying and Selling at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.10% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.